DOP2009000208A - Métodos de tratamiento del cáncer mediante administración de combinaciones de il-18 humana - Google Patents
Métodos de tratamiento del cáncer mediante administración de combinaciones de il-18 humanaInfo
- Publication number
- DOP2009000208A DOP2009000208A DO2009000208A DO2009000208A DOP2009000208A DO P2009000208 A DOP2009000208 A DO P2009000208A DO 2009000208 A DO2009000208 A DO 2009000208A DO 2009000208 A DO2009000208 A DO 2009000208A DO P2009000208 A DOP2009000208 A DO P2009000208A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- combinations
- human
- treatment
- cancer
- administration
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
La presente invención se refiere en general al uso de combinaciones de la IL-18 humana en el tratamiento de diversas formas de tumores sólidos y linfomas. En particular, la presente invención se refiere a: (1) combinaciones de la IL-18 humana con anticuerpos monoclonales contra anfígenos que se expresan en la superficie de células cancerosas; y (2) combinaciones IL-18 humana con agentes terapéuticos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89685507P | 2007-03-23 | 2007-03-23 | |
US95200207P | 2007-07-26 | 2007-07-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2009000208A true DOP2009000208A (es) | 2010-03-31 |
Family
ID=39788932
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2009000208A DOP2009000208A (es) | 2007-03-23 | 2009-08-28 | Métodos de tratamiento del cáncer mediante administración de combinaciones de il-18 humana |
DO2009000220A DOP2009000220A (es) | 2007-03-23 | 2009-09-18 | Combinado de humano il-18 y anticuerpo anti cd20 para el tratamiento del cancer |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2009000220A DOP2009000220A (es) | 2007-03-23 | 2009-09-18 | Combinado de humano il-18 y anticuerpo anti cd20 para el tratamiento del cancer |
Country Status (21)
Country | Link |
---|---|
US (4) | US20080274078A1 (es) |
EP (3) | EP2136841A4 (es) |
JP (2) | JP2010522239A (es) |
KR (2) | KR20100015798A (es) |
CN (1) | CN101678102A (es) |
AR (2) | AR065803A1 (es) |
AU (2) | AU2008231114A1 (es) |
BR (2) | BRPI0809079A2 (es) |
CA (2) | CA2681851A1 (es) |
CL (2) | CL2008000818A1 (es) |
CR (2) | CR10996A (es) |
DO (2) | DOP2009000208A (es) |
EA (2) | EA200970884A1 (es) |
IL (2) | IL200525A0 (es) |
MA (2) | MA31265B1 (es) |
MX (2) | MX2009010269A (es) |
NZ (1) | NZ579179A (es) |
PE (2) | PE20090190A1 (es) |
SG (1) | SG171674A1 (es) |
TW (2) | TW200906436A (es) |
WO (2) | WO2008118733A2 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI373343B (en) * | 2000-02-10 | 2012-10-01 | Abbott Gmbh & Co Kg | Antibodies that bind human interleukin-18 and methods of making and using |
US7968684B2 (en) | 2003-11-12 | 2011-06-28 | Abbott Laboratories | IL-18 binding proteins |
AR065803A1 (es) * | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento |
TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
SI3134124T1 (sl) | 2014-04-25 | 2019-06-28 | Pierre Fabre Medicament | Konjugat protitelesa zdravila IGF-1R in uporaba le-tega za zdravljenje raka |
MX2016013999A (es) | 2014-04-25 | 2017-05-30 | Pf Medicament | Conjugado farmaco-anticuerpo y su uso para el tratamiento contra el cancer. |
US11219672B2 (en) | 2014-08-07 | 2022-01-11 | Haruki Okamura | Therapeutic agent for cancer which comprises combination of IL-18 and molecule-targeting antibody |
WO2016126615A1 (en) * | 2015-02-03 | 2016-08-11 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
WO2022115946A1 (en) * | 2020-12-02 | 2022-06-09 | The Royal Institution For The Advancement Of Learning/Mcgill University | Therapeutic applications of type 1 insulin-like growth factor (igf-1) receptor antagonists |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69519454T2 (de) | 1994-07-14 | 2001-05-03 | Hayashibara Biochem Lab | Protein, das Interferon-Gamma Herstellung induziert und monoklonaler Antikörper dagegen |
JP4004088B2 (ja) | 1995-09-26 | 2007-11-07 | 株式会社林原生物化学研究所 | 免疫担当細胞においてインターフェロン−γの産生を誘導する蛋白質 |
US7135458B1 (en) * | 1995-11-15 | 2006-11-14 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Interferon-γ inducing polypeptide, pharmaceutical composition thereof, monoclonal antibody thereto, and methods of use |
TW464656B (en) | 1994-11-15 | 2001-11-21 | Hayashibara Biochem Lab | Interferon-gamma production inducing polypeptide monoclonal antibody, and agent for interferon-gamma susceptive disease |
US5680795A (en) | 1995-07-05 | 1997-10-28 | Norco Inc. | Mechanical drive assembly incorporating counter-spring biassed radially-adjustable rollers |
JP4024366B2 (ja) * | 1996-11-29 | 2007-12-19 | 株式会社林原生物化学研究所 | ポリペプチド |
US6787132B1 (en) * | 1997-12-04 | 2004-09-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Combined chemo-immunotherapy with liposomal drugs and cytokines |
TWI227136B (en) * | 1998-05-21 | 2005-02-01 | Smithkline Beecham Corp | Novel pharmaceutical composition for the prevention and/or treatment of cancer |
PT1292697E (pt) | 2000-06-15 | 2009-10-28 | Smithkline Beecham Corp | Método para a preparação de um polipéptido il-18 fisiologicamente activo |
US20020094323A1 (en) * | 2000-10-12 | 2002-07-18 | Kristoffer Hellstrand | Methods and compositions for promoting the maturation of monocytes |
CA2476166C (en) * | 2002-02-14 | 2011-11-15 | Immunomedics, Inc. | Anti-cd20 antibodies and fusion proteins thereof and methods of use |
JP2005526501A (ja) * | 2002-02-21 | 2005-09-08 | デューク・ユニヴァーシティ | 自己免疫疾患用の試薬および治療方法 |
US7524814B2 (en) * | 2002-09-16 | 2009-04-28 | Agennix, Inc. | Lactoferrin compositions and methods of wound treatment |
KR20050073488A (ko) * | 2002-10-08 | 2005-07-13 | 이뮤노메딕스, 인코오포레이티드 | Ⅲ종 항-cea 단클론 항체들 및 치료제들을 이용한 조합치료법 |
SI1558648T1 (sl) * | 2002-10-17 | 2012-05-31 | Genmab As | Človeška monoklonalna protitelesa proti CD |
US7534427B2 (en) * | 2002-12-31 | 2009-05-19 | Immunomedics, Inc. | Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins |
WO2004091517A2 (en) * | 2003-04-15 | 2004-10-28 | Smithkline Beecham Corporation | Conjugates comprising human il-18 and substitution mutants thereof |
US20050075277A1 (en) * | 2003-07-10 | 2005-04-07 | Agennix Incorporated | Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects |
US7109304B2 (en) * | 2003-07-31 | 2006-09-19 | Immunomedics, Inc. | Humanized anti-CD19 antibodies |
RU2412199C2 (ru) * | 2005-04-18 | 2011-02-20 | Ново Нордиск А/С | Варианты ил-21 |
ES2530265T3 (es) * | 2005-07-21 | 2015-02-27 | Genmab A/S | Ensayos de potencia de unión de una sustancia medicamentosa de anticuerpo a un receptor FC |
WO2008008981A1 (en) * | 2006-07-13 | 2008-01-17 | Zymogenetics, Inc. | Interleukin 21 and tyrosine kinase inhibitor combination therapy |
CA2662609A1 (en) * | 2006-09-14 | 2008-03-20 | The Trustees Of The University Of Pennsylvania | Modulation of regulatory t cells by human il-18 |
AR065803A1 (es) * | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento |
-
2008
- 2008-03-19 AR ARP080101155A patent/AR065803A1/es not_active Application Discontinuation
- 2008-03-19 PE PE2008000506A patent/PE20090190A1/es not_active Application Discontinuation
- 2008-03-20 EP EP08744104A patent/EP2136841A4/en not_active Withdrawn
- 2008-03-20 US US12/052,120 patent/US20080274078A1/en not_active Abandoned
- 2008-03-20 KR KR1020097022076A patent/KR20100015798A/ko not_active Application Discontinuation
- 2008-03-20 AU AU2008231114A patent/AU2008231114A1/en not_active Abandoned
- 2008-03-20 EP EP10192703A patent/EP2338514A1/en not_active Withdrawn
- 2008-03-20 KR KR1020097019795A patent/KR20100014530A/ko not_active Application Discontinuation
- 2008-03-20 SG SG201103315-6A patent/SG171674A1/en unknown
- 2008-03-20 EA EA200970884A patent/EA200970884A1/ru unknown
- 2008-03-20 BR BRPI0809079-3A patent/BRPI0809079A2/pt not_active IP Right Cessation
- 2008-03-20 WO PCT/US2008/057615 patent/WO2008118733A2/en active Application Filing
- 2008-03-20 MX MX2009010269A patent/MX2009010269A/es not_active Application Discontinuation
- 2008-03-20 CL CL200800818A patent/CL2008000818A1/es unknown
- 2008-03-20 US US12/532,727 patent/US20100111945A1/en not_active Abandoned
- 2008-03-20 NZ NZ579179A patent/NZ579179A/en not_active IP Right Cessation
- 2008-03-20 CN CN200880017106A patent/CN101678102A/zh active Pending
- 2008-03-20 US US12/532,776 patent/US20100196310A1/en not_active Abandoned
- 2008-03-20 US US12/052,278 patent/US20090035258A1/en not_active Abandoned
- 2008-03-20 CA CA002681851A patent/CA2681851A1/en not_active Abandoned
- 2008-03-20 JP JP2010501096A patent/JP2010522239A/ja not_active Withdrawn
- 2008-03-20 CA CA002681827A patent/CA2681827A1/en not_active Abandoned
- 2008-03-20 JP JP2009554732A patent/JP2010522200A/ja active Pending
- 2008-03-20 AU AU2008231025A patent/AU2008231025A1/en not_active Abandoned
- 2008-03-20 EA EA200970885A patent/EA200970885A1/ru unknown
- 2008-03-20 MX MX2009010271A patent/MX2009010271A/es unknown
- 2008-03-20 EP EP08744109A patent/EP2129398A4/en not_active Withdrawn
- 2008-03-20 WO PCT/US2008/057620 patent/WO2008118736A1/en active Application Filing
- 2008-03-20 BR BRPI0808943-4A patent/BRPI0808943A2/pt not_active IP Right Cessation
- 2008-03-21 TW TW097109963A patent/TW200906436A/zh unknown
- 2008-03-24 TW TW097110406A patent/TW200904469A/zh unknown
- 2008-03-24 CL CL200800842A patent/CL2008000842A1/es unknown
- 2008-03-24 PE PE2008000532A patent/PE20090184A1/es not_active Application Discontinuation
- 2008-03-25 AR ARP080101195A patent/AR065818A1/es not_active Application Discontinuation
-
2009
- 2009-08-20 IL IL200525A patent/IL200525A0/en unknown
- 2009-08-26 CR CR10996A patent/CR10996A/es not_active Application Discontinuation
- 2009-08-28 DO DO2009000208A patent/DOP2009000208A/es unknown
- 2009-09-10 IL IL200863A patent/IL200863A0/en unknown
- 2009-09-18 DO DO2009000220A patent/DOP2009000220A/es unknown
- 2009-09-24 MA MA32235A patent/MA31265B1/fr unknown
- 2009-09-24 MA MA32234A patent/MA31264B1/fr unknown
- 2009-10-23 CR CR11075A patent/CR11075A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2009000208A (es) | Métodos de tratamiento del cáncer mediante administración de combinaciones de il-18 humana | |
CL2017001580A1 (es) | Anticuerpo o fragmento de anticuerpo contra cd38 anticuerpo humanizado, conjugado del anticuerpo con un compuesto citotoxico composición farmacéutica con dichos anticuerpos uso de los anticuerpos para tratar cáncer o enfermedad autoinmune método para diagnosticar cáncer polinucleotido vector y célula huésped. | |
NI201300119A (es) | Uso del anticuerpo anti - cd19 inmunoconjugado con maitansinoide para el tratatamiento del síntoma tumores de células b. | |
CR20110553A (es) | Terapia complementaria contra el cáncer | |
ES2422605T3 (es) | Anticuerpo contra klotho-beta para utilizar en el tratamiento de tumores, cáncer o trastornos proliferativos celulares | |
UA108618C2 (uk) | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
AR074203A1 (es) | Terapia anti-angiogenesis para el tratamiento del cancer de mama. kit. uso. | |
MX2010003815A (es) | Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con un agente activo anti-bcl-2. | |
UY32882A (es) | (heteroarilmetil) tiohidantoínas sustituidas | |
ECSP12011943A (es) | Antagonistas de espiro-oxindol de mdm2 | |
BR112015025711A8 (pt) | uso de ibrutinibe e coposição farmacêutica compreendendo ibrutinibe e um agente anticâncer | |
EA201070463A1 (ru) | Комбинированная терапия с использованием конъюгатов антитело-лекарственное средство | |
EA201391351A1 (ru) | Способы повышения эффективности folr1 терапии рака | |
CL2008001373A1 (es) | Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer. | |
WO2015009726A3 (en) | Medical uses of cd38 agonists | |
UY29249A1 (es) | Agentes citotóxicos que comprenden taxanos nuevos | |
CR10143A (es) | Antígenos de ácido des-n-acetil-siálico, anticuerpos para los mismos y métodos de uso en la terapia del cáncer | |
CL2011000119A1 (es) | Compuestos derivados de triazolo[4,3-a]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer. | |
ES2422429T3 (es) | Diagnóstico del cáncer de próstata | |
ECSP10010729A (es) | Péptidos dirigidos a crkl | |
PH12020550598A1 (en) | Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells | |
BR112013033544A2 (pt) | dosagem e administração de anticorpos anti-erbb3 em combinação com paclitaxel para tratamento de cânceres ginecológicos | |
AR081321A1 (es) | N-cadherina: un blanco para el diagnostico y la terapia del cancer | |
WO2015023694A3 (en) | Method for enhancing tumor growth | |
ATE499378T1 (de) | Anthracyclinderivate |